Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation

Vaccine

Volumn 28, Issue 51, 2010, Pages 8203-8209

  Bråve, Andreas ^a,b   Gudmundsdotter, Lindvi ^a,b   Sandström, Eric ^b   Haller, B Kristian ^b   Hallengärd, David ^a,b   Maltais, Anna Karin ^c   King, Alan D ^d   Stout, Richard R ^e   Blomberg, Pontus ^f   Höglund, Urban ^g   Hejdeman, Bo ^b   Biberfeld, Gunnel ^a   Wahren, Britta ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karolinska Institute Science Park   (Sweden)

^d Arvid Wallgrens Backe 20   (United States)

^e Bioject Medical Technologies   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Visionar Biomedical AB   (Sweden)

Author keywords

Bioject; Dermal; Electroporation; HIV; Plasmid DNA; Skin

Indexed keywords

GENOMIC DNA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL CHEMISTRY; CONTROLLED STUDY; DNA EXTRACTION; DNA INTEGRATION; DRUG SAFETY; ELECTROPORATION; FEMALE; GEL ELECTROPHORESIS; GENETIC ASSOCIATION; HEALTH STATUS; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE; JET INJECTION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

AIDS VACCINES; ANIMALS; ELECTROPORATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRADERMAL; MALE; MICE; MICE, INBRED BALB C; PLASMIDS; SKIN; VACCINES, DNA; VACCINES, SYNTHETIC; VIRUS INTEGRATION;

EID: 78649658963     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.108     Document Type: Article

References (33)

1. Bacardi D., Amador-Canizares Y., Cosme K., Urquiza D., Suarez J., Marante J., et al. Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus. Hum Exp Toxicol 2009, 28(August (8)):479-491.
2. Gravier R., Dory D., Laurentie M., Bougeard S., Cariolet R., Jestin A. In vivo tissue distribution and kinetics of a pseudorabies virus plasmid DNA vaccine after intramuscular injection in swine. Vaccine 2007, 25(September (39-40)):6930-6938.
3. Hanke T., McMichael A.J., Samuel R.V., Powell L.A., McLoughlin L., Crome S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 2002, 21(November (1-2)):108-114.
4. Kim B.M., Lee D.S., Choi J.H., Kim C.Y., Son M., Suh Y.S., et al. In vivo kinetics and biodistribution of a HIV-1 DNA vaccine after administration in mice. Arch Pharm Res 2003, 26(June (6)):493-498.
5. Manam S., Ledwith B.J., Barnum A.B., Troilo P.J., Pauley C.J., Harper L.B., et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000, 43(4-6):273-281.
6. Parker S.E., Borellini F., Wenk M.L., Hobart P., Hoffman S.L., Hedstrom R., et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999, 10(March (5)):741-758.
7. Quezada A., Larson J., French M., Ponce R., Perrard J., Durland R., et al. Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 2004, 56(February (2)):177-185.
8. Ramirez K., Barry E.M., Ulmer J., Stout R., Szabo J., Manetz S., et al. Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen. Hum Gene Ther 2008, 19(May (5)):522-531.
9. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006, 91(June (2)):610-619.
10. Winegar R.A., Monforte J.A., Suing K.D., O'Loughlin K.G., Rudd C.J., Macgregor J.T. Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. Hum Gene Ther 1996, 7(November (17)):2185-2194.
11. Zhang H.Y., Sun S.H., Guo Y.J., Chen Z.H., Huang L., Gao Y.J., et al. Tissue distribution of a plasmid DNA containing epitopes of foot-and-mouth disease virus in mice. Vaccine 2005, 23(December (48-49)):5632-5640.
12. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgonne H., Kimman T.G. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006, 2(March-April (2)):45-53.
13. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004, 11(April (8)):711-721.
14. Brave A., Ljungberg K., Boberg A., Rollman E., Isaguliants M., Lundgren B., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005, 12(December (6)):1197-1205.
15. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(November (10)):1482-1490.
16. Bakari M. A low dose multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA. AIDS Vaccine conference, 2009 2009.
17. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002, 302(October (1)):44-57.
18. Rollman E., Brave A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005, 7(November (14)):1414-1423.
19. Brave A., Ljungberg K., Boberg A., Rollman E., Engstrom G., Hinkula J., et al. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 2006, 24(May (21)):4524-4526.
20. Roos A.K., Eriksson F., Walters D.C., Pisa P., King A.D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther 2009, 17(September (9)):1637-1642.
21. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999, 10(March (5)):759-768.
22. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351(May (9112)):1320-1325.
23. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178(July (1)):92-100.
24. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(May (10)):5257-5269.
25. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96(April (8)):4262-4267.
26. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22(June (19)):2489-2493.
27. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164(May (9)):4635-4640.
28. Long Y.C., Jaichandran S., Ho L.P., Tien S.L., Tan S.Y., Kon O.L. FVIII gene delivery by muscle electroporation corrects murine hemophilia A. J Gene Med 2005, 7(April (4)):494-505.
29. Luxembourg A., Evans C.F., Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 2007, 7(November (11)):1647-1664.
30. Roos A.K., Eriksson F., Timmons J.A., Gerhardt J., Nyman U., Gudmundsdotter L., et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 2009, 4(9):e7226.
31. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000, 43(4-6):258-272.
32. Ahlen G., Soderholm J., Tjelle T., Kjeken R., Frelin L., Hoglund U., et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007, 179(October (7)):4741-4753.
33. Chalberg T.W., Genise H.L., Vollrath D. Calos MP. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci 2005, 46(June (6)):2140-2146.